Solid Biosciences Inc., a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has reached two important milestones in the development of its investigational gene therapy SGT-212 for Friedreich’s ataxia (FA). The company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SGT-212, and that the first participant has been dosed in FALCON, a Phase 1b first-in-human clinical trial evaluating the therapy in patients with FA.
Friedreich’s ataxia is a rare, inherited neurodegenerative disease that causes progressive damage to the nervous system and heart, often leading to severe disability and premature death. Current treatment options are limited, and there remains a significant unmet medical need for therapies that can address the underlying cause of the disease. The FDA’s Orphan Drug designation is intended to encourage the development of treatments for rare conditions by providing benefits such as development incentives, tax credits, and potential market exclusivity if approved.
In addition to Orphan Drug designation, SGT-212 has also received Fast Track and Rare Pediatric Disease designations from the FDA, further highlighting the agency’s recognition of both the seriousness of FA and the potential of the investigational therapy. According to Solid Biosciences, these regulatory designations could help streamline the development process and support more frequent interactions with regulators as the program advances.
SGT-212 is a first-in-class gene therapy designed to address the neurologic, cardiac, and systemic manifestations of Friedreich’s ataxia, which are key contributors to disease-related illness and mortality. The therapy uses a novel dual-route administration approach. It is delivered through a precise, stereotactic, MRI-guided infusion into the intradentate nuclei of the cerebellum, followed by an intravenous infusion. This strategy is intended to broadly target affected tissues and restore therapeutic levels of frataxin, the protein that is deficient in patients with FA.
Jessie Hanrahan, Ph.D., Chief Regulatory and Preclinical Operations Officer at Solid Biosciences, said the regulatory designations underscore both the urgent needs of the FA community and the therapeutic promise of SGT-212’s innovative delivery approach. She added that Solid looks forward to working closely with regulators as the company seeks to advance a potential new treatment option for patients living with this rare and debilitating disease.
With the initiation of the FALCON trial, Solid Biosciences is now moving SGT-212 into clinical evaluation, marking a key step toward determining its safety, tolerability, and early signs of therapeutic activity in humans.